MSD：WINREVAIR™Sotatercept received marketing approval
Today, PAH treatment in China has reached a historic breakthrough! On June 8, it was officially announced that the world’s first fully human biologic targeting the core pathological mechanism of PAH — Sotatercept for Injection (brand name: Winrevair®) — has been approved for marketing in China. Specifically designed for adult patients with PAH (WHO Group 1) classified as WHO Functional Class (WHO FC) II-III, this therapy successfully fills the gap in etiological treatment for PAH in China and completely reshapes the domestic PAH treatment landscape.
Pulmonary arterial hypertension (PAH) is an insidious and dangerous severe cardiovascular disease, often referred to by patients as the “invisible killer of the heart and lungs.” It progressively impairs pulmonary vascular function, significantly reduces patients’ exercise capacity and ability to perform daily activities, and carries an extremely poor prognosis, with a 5-year mortality rate of up to 40% for newly diagnosed patients. For a long time, it has been a refractory disease that plagues clinical practice and afflicts countless families.
Prior to this, traditional PAH treatment regimens in China were largely focused on symptomatic intervention. The core objectives were to relieve clinical symptoms such as chest tightness and dyspnea, and to delay disease progression — a “symptom-management” approach that could not fundamentally block or reverse the pathological progression of the disease. Patients continued to face the challenges of recurrent symptoms, persistent deterioration, and poor prognosis.
The approval of sotatercept has completely broken through these treatment limitations. As the world’s first and currently only approved activin signaling pathway inhibitor, and the first fully human fusion protein targeting pulmonary vascular remodeling, it moves beyond traditional symptomatic logic and directly addresses the core pathogenesis of PAH. By precisely inhibiting abnormal cell proliferation, it effectively blocks the progressive pathology of pulmonary vessels, thereby reversing pulmonary vascular remodeling, improving cardiopulmonary hemodynamics and heart failure status, and achieving effective intervention at the root cause of the disease. This marks the official entry of domestic PAH treatment into a new era of “etiological and curative” therapy.
The efficacy and safety of this revolutionary new drug have been fully validated by international authoritative clinical studies. Data from the global multicenter Phase III STELLAR trial showed that, on top of background therapy, patients with PAH receiving sotatercept experienced a significant improvement of 40.8 meters in 6-minute walk distance at 24 weeks, representing a substantial enhancement in exercise capacity. More importantly, the risk of clinical worsening was reduced by 84%, effectively lowering the incidence of death, hospitalization, and lung transplantation, and greatly improving the long-term prognosis for PAH patients.
With its disruptive mechanism and excellent clinical efficacy, sotatercept has already gained global recognition. The drug was first approved by the U.S. FDA in 2024 and is now approved in over 50 countries and regions worldwide. It has been listed by international guidelines as a core innovative therapy for PAH and is widely regarded as a landmark breakthrough in the global PAH treatment landscape.
With sotatercept officially launched in China, PAH patients in the country finally have access to an innovative, internationally aligned curative treatment option. From merely “surviving” in the past, patients can now look forward to improved quality of life, reversal of disease progression, and a return to normal life. This drug, with its entirely novel mechanism, has dispelled the shadow of disease for countless PAH patients and their families. Looking ahead, we hope this blockbuster new drug will continue to benefit domestic patients, breaking the shackles of disease with the power of innovation and restoring vitality to more PAH patients.
Buy WINREVAIR™（Sotatercept） from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
